Global Bovine Respiratory Disease Treatment Market Size study & Forecast, by Material Treatment Type (Vaccines, Antibiotics, NSAIDs, Immunomodulators, and Other Treatment Types), Disease Type (Lower Respiratory Tract Infections, Upper Respiratory Tract In

Global Bovine Respiratory Disease Treatment Market Size study & Forecast, by Material Treatment Type (Vaccines, Antibiotics, NSAIDs, Immunomodulators, and Other Treatment Types), Disease Type (Lower Respiratory Tract Infections, Upper Respiratory Tract Infections, Diphtheria), and Regional Analysis, 2022-2029

Global Bovine Respiratory Disease Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2029. Bovine Respiratory Disease Treatment refers to the common diseases occur to cattle globally. It includes infectious bovine rhinotracheitis (IBR), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea (BVD), and parainfluenza type-3 virus (PI-3). The Bovine Respiratory Disease Treatment market is expanding because of factors such as the growing consumption of beef and rising incidences of bovine respiratory diseases

According to the article published in September 2022, titled ""World Beef Consumption: Ranking of Countries (USDA),"" global beef consumption stood at 147.34 billion pounds in 2020. The United States consumed the most beef in 2020, followed by China, the European Union, Brazil, and India.
Whereas, rising cases of Diphtheria and growing R&D activities by market players create lucrative opportunities for the market. However, the lack of skilled veterinarians hampers the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bovine Respiratory Disease Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing production and consumption of bovine meat and rising cases of BRD, and increasing awareness of bovine respiratory treatment Whereas North America is expected to grow significantly during the forecast period, owing to factors such as increasing technological advances in products to monitor BRD and growing penetration of market players etc. in the forecast period


Major market players included in this report are:
Bimeda
Boehringer Ingelheim GmbH
Ceva
Elanco
Krka UK Ltd
Merial
Merck & Co. Inc.
Vetoquinol
Virbac
Zoetis Inc.

Recent Developments in the Market:
 In August 2022, the researchers and bioinformatics core of University of Lethbridge’s Southern Alberta Genome Science Centre (SAGSC) collaborated with scientists at agriculture and agri-food Canada with the aim to develop viable solutions to mitigate bovine respiratory diseases.
 In March 2022, Merck Animal Health, a division of Merck & Co., Inc., known as MSD Animal Health outside the United States and Canada, received FDA approval for AROVYN (tulathromycin injection) - a broad-spectrum, prescription antibiotic that treats the major organisms associated with bovine respiratory disease (BRD), foot rot, and pinkeye.

Global Bovine Respiratory Disease Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Treatment, Disease, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:
By Treatment:
Vaccines,
Antibiotics,
NSAIDs,
Immunomodulators,
Other Treatment Types

By Disease:
Lower Respiratory Tract Infections,
Upper Respiratory Tract Infections,
Diphtheria

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Bimeda
Boehringer Ingelheim GmbH
Ceva
Elanco
Krka UK Ltd
Merial
Merck & Co. Inc.
Vetoquinol
Virbac
Zoetis Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.